{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:04:19Z","timestamp":1790661859827,"version":"4.1.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Transplant."],"DOI":"10.3389\/frtra.2026.1966659","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:46:16Z","timestamp":1790660776000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond pulmonary arterial hypertension: sotatercept across the advanced heart failure and transplant continuum"],"prefix":"10.3389","volume":"5","author":[{"given":"Andrew","family":"Xanthopoulos","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Hospital of Larissa, Faculty of Medicine, University of Thessaly","place":["Larissa, Greece"]},{"name":"School of Medicine, European University Cyprus","place":["Nicosia, Cyprus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Kourek","sequence":"additional","affiliation":[{"name":"Department of Cardiology, 417 Army Share Fund Hospital of Athens (NIMTS)","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios E.","family":"Magouliotis","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery Research, Lankenau Institute for Medical Research","place":["Wynnewood, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippos","family":"Triposkiadis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Larissa, Faculty of Medicine, University of Thessaly","place":["Larissa, Greece"]},{"name":"School of Medicine, European University Cyprus","place":["Nicosia, Cyprus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/10600280251358959","article-title":"Sotatercept: a new frontier in pulmonary arterial hypertension treatment","volume":"60","author":"Truong","year":"2026","journal-title":"Ann Pharmacother"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2301107","DOI":"10.1183\/13993003.01107-2023","article-title":"Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial","volume":"62","author":"Souza","year":"2023","journal-title":"Eur Respir J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3390\/ph19050760","article-title":"Sotatercept as an add-on to background therapy in idiopathic pulmonary arterial hypertension: insights from a real-world cohort","volume":"19","author":"Filippatos","year":"2026","journal-title":"Pharmaceuticals (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa2415160","article-title":"Sotatercept in patients with pulmonary arterial hypertension at high risk for death","volume":"392","author":"Humbert","year":"2025","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa2508170","article-title":"Sotatercept for pulmonary arterial hypertension within the first year after diagnosis","volume":"393","author":"McLaughlin","year":"2025","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17534666261459209","DOI":"10.1177\/17534666261459209","article-title":"Clinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data","volume":"20","author":"Murad","year":"2026","journal-title":"Ther Adv Respir Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.125.076913","article-title":"Acute hemodynamic effects of sotatercept","volume":"152","author":"Kremer","year":"2025","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"102714","DOI":"10.1016\/j.jocmr.2026.102714","article-title":"Sotatercept improves right ventricular function but is associated with new or worsening pericardial effusions: a cardiovascular magnetic resonance study in intermediate-high risk pulmonary arterial hypertension","volume":"28","author":"Virsinskaite","year":"2026","journal-title":"J Cardiovasc Magn Reson"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1161\/CIRCULATIONAHA.126.079918","article-title":"Sotatercept for combined post- and precapillary pulmonary hypertension associated with heart failure: results from the phase 2, randomized, placebo-controlled CADENCE study","volume":"153","author":"Gomberg-Maitland","year":"2026","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2026.04.010","article-title":"The CADENCE trial: activin type II receptor ligand trapping with sotatercept as first prospective proof-of-concept for the adipokine hypothesis of heart failure with preserved ejection fraction","author":"Packer","year":"2026","journal-title":"J Card Fail"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s10741-022-10239-5","article-title":"Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure","volume":"27","author":"Triposkiadis","year":"2022","journal-title":"Heart Fail Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2026.07.022","article-title":"Pulmonary arterial hypertension-targeted therapy for pulmonary hypertension associated with left heart disease: Bayesian and frequentist meta-analysis of randomized controlled trials","author":"Kiyohara","year":"2026","journal-title":"Am J Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.healun.2024.11.037","article-title":"Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: a pooled analysis of PULSAR and STELLAR","volume":"44","author":"Gomberg-Maitland","year":"2025","journal-title":"J Heart Lung Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e015897","DOI":"10.1161\/JAHA.119.015897","article-title":"Postimplant phosphodiesterase type 5 inhibitors use is associated with lower rates of thrombotic events after left ventricular assist device implantation","volume":"9","author":"Xanthopoulos","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jchf.2021.09.008","article-title":"Postimplant phosphodiesterase-5 inhibitor use in centrifugal flow left ventricular assist devices","volume":"10","author":"Xanthopoulos","year":"2022","journal-title":"JACC Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"102604","DOI":"10.1016\/j.jchf.2025.102604","article-title":"Challenges for research in the LVAD population","volume":"13","author":"Xanthopoulos","year":"2025","journal-title":"JACC Heart Fail"},{"key":"B19","doi-asserted-by":"publisher","first-page":"102756","DOI":"10.1016\/j.jchf.2025.102756","article-title":"From small cavities to big gains: phosphodiesterase 5 inhibitors in LVAD care","volume":"14","author":"Xanthopoulos","year":"2026","journal-title":"JACC Heart Fail"},{"key":"B20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.healun.2026.02.819","article-title":"Sotatercept for right ventricular failure following heart transplantation in a patient with elevated pulmonary vascular resistance: a case report (conference abstract)","volume":"45","author":"Fabbri","year":"2026","journal-title":"J Heart Lung Transplant"}],"container-title":["Frontiers in Transplantation"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2026.1966659\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:46:17Z","timestamp":1790660777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2026.1966659\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":20,"alternative-id":["10.3389\/frtra.2026.1966659"],"URL":"https:\/\/doi.org\/10.3389\/frtra.2026.1966659","relation":{},"ISSN":["2813-2440"],"issn-type":[{"value":"2813-2440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1966659"}}